VALIDOGEN Track record

VALIDOGEN (formerly VTU Technology) - well established and globally recognized contract research and technology licensing business in the field of protein production process development
VALIDOGEN has profound experience in the design of expression strains and bioprocesses for the production of a wide range of proteins for diverse applications serving customers from a variety of different industries. VALIDOGEN produces all types of recombinant proteins from cytokines, growth factors, hormones, serum proteins to fusion proteins (Fc-and albumin fusion), protein scaffolds, antibody fragments and vaccine antigens, enzymes or allergens.


Contract Research Projects

  • Serving customers for more than 10 years
  • Customers from different industry sectors
  • Projects with industry giants as well as start-up companies from all continents

Licenses & Tech Transfer

  • Commercial licenses granted to licensees from different industry sectors
  • Successful technology transfers – Scale-up to several 1000 l (100k max)
  • Clinical study material from VALIDOGEN P. pastoris in Phase I

Advanced Technology Platform

  • UNLOCK PICHIA - proprietary Pichia pastoris protein expression toolbox
  • Proven and globally recognized cutting-edge technology platform
  • Unmatched in terms of yield, development timelines, quality & safety

Intellectual Property

  • Key patents protecting technological leadership position
  • Firm IP position, several patent families
  • Freedom to operate

Development & Collaborations

  • Non exclusive technology development with Boehringer Ingelheim
  • Several academic collaborations
  • Several B2B collaborations

Team & Facilities

  • Highly skilled and experienced team
  • Strong background in protein production and optimized workflows
  • State of the art laboratory infrastructure and production equipment



Sign up to our mailing list to keep up with latest developments and information around Pichia based protein expression.
Yes, I agree with the regular receipt of the VALIDOGEN newsletter. The subscription to the newsletter can be canceled at any time
(see privacy policy)


VALIDOGEN to present at PICHIA 2021, online conference, March 24 - April 1

Pichia 2021, online conference "Don't miss latest insights into UNLOCK ...

New case study on VHH antibody expression underlines the power of UNLOCK PICHIA

We conducted a series of case studies, demonstrating the yield-enhancing ...


Company folder and brochures

All downloads
Tablet Potrait-Mode gerade in Arbeit, bitte drehen Sie das Tablet in den Landscape-Mode.